These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19277878)

  • 21. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells.
    Momeny M; Shamsaiegahkani S; Kashani B; Hamzehlou S; Esmaeili F; Yousefi H; Irani S; Mousavi SA; Ghaffari SH
    Life Sci; 2021 Dec; 287():120100. PubMed ID: 34715143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
    Lobo MR; Kukino A; Tran H; Schabel MC; Springer CS; Gillespie GY; Grafe MR; Woltjer RL; Pike MM
    PLoS One; 2015; 10(12):e0144488. PubMed ID: 26645398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts.
    Oku T; Tjuvajev JG; Miyagawa T; Sasajima T; Joshi A; Joshi R; Finn R; Claffey KP; Blasberg RG
    Cancer Res; 1998 Sep; 58(18):4185-92. PubMed ID: 9751633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
    Claes A; Gambarota G; Hamans B; van Tellingen O; Wesseling P; Maass C; Heerschap A; Leenders W
    Int J Cancer; 2008 May; 122(9):1981-6. PubMed ID: 18081012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oedema extension in cerebral metastasis and correlation with the expression of nitric oxide synthase isozymes (NOS I-III).
    Ludwig HC; Ahkavan-Shigari R; Rausch S; Schallock K; Quentin C; Ziegler D; Bockermann V; Markakis E
    Anticancer Res; 2000; 20(1A):305-10. PubMed ID: 10769672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
    Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models.
    Jun KH; Lee JE; Kim SH; Jung JH; Choi HJ; Kim YI; Chin HM; Yang SH
    Oncol Rep; 2015 Oct; 34(4):2047-53. PubMed ID: 26260219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia?
    Feng S; Huang Y; Chen Z
    Med Hypotheses; 2011 May; 76(5):618-21. PubMed ID: 21398042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
    Pham K; Luo D; Siemann DW; Law BK; Reynolds BA; Hothi P; Foltz G; Harrison JK
    Cancer Lett; 2015 Apr; 360(1):60-7. PubMed ID: 25676691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis.
    Weis S; Cui J; Barnes L; Cheresh D
    J Cell Biol; 2004 Oct; 167(2):223-9. PubMed ID: 15504909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
    Wong HK; Lahdenranta J; Kamoun WS; Chan AW; McClatchey AI; Plotkin SR; Jain RK; di Tomaso E
    Cancer Res; 2010 May; 70(9):3483-93. PubMed ID: 20406973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model.
    Yoshimoto M; Kinuya S; Kawashima A; Nishii R; Yokoyama K; Kawai K
    Nucl Med Biol; 2006 Nov; 33(8):963-9. PubMed ID: 17127168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D.
    Moffat BA; Chen M; Kariaapper MS; Hamstra DA; Hall DE; Stojanovska J; Johnson TD; Blaivas M; Kumar M; Chenevert TL; Rehemtulla A; Ross BD
    Clin Cancer Res; 2006 Mar; 12(5):1525-32. PubMed ID: 16533777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
    Medinger M; Esser N; Zirrgiebel U; Ryan A; Jürgensmeier JM; Drevs J
    Anticancer Res; 2009 Dec; 29(12):5065-76. PubMed ID: 20044618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
    Gerstner ER; Duda DG; di Tomaso E; Ryg PA; Loeffler JS; Sorensen AG; Ivy P; Jain RK; Batchelor TT
    Nat Rev Clin Oncol; 2009 Apr; 6(4):229-36. PubMed ID: 19333229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
    Melnyk O; Zimmerman M; Kim KJ; Shuman M
    J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
    Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.